Upon opening ACCC’s first Metastatic Breast Cancer Summit in Washington, D.C., ACCC Executive Director Christian G. Downs, MHA, JD, remarked, “Everyone knows what we have to do; it’s more difficult to know how to do it. Today is the ‘how to’ part.” The summit was held on October 7, 2019.
The “what,” said Downs, are the largely agreed-upon goals that must be realized before all patients with metastatic breast cancer are able to access the full spectrum of clinical and supportive care services. These goals—such as equal access to psychosocial care, clinical trials, financial resources, and treatment options—will remain lofty ideals until the actions that can make them realities are widely adopted.
By bringing together a variety of stakeholders in the cancer care community, the day-long summit's aim was to identify practical action items that cancer programs and practices—large and small—can implement now to enhance and expand holistic care in their metastatic breast cancer patient population. Summit invitees included professionals from across the multidisciplinary cancer care team: social workers, program managers, nurse practitioners, oncologists, chaplains, nurse navigators, patient advocates, financial navigators, and others. A few of the most knowledgeable specialists—people who themselves have been diagnosed with metastatic breast cancer—were also present.
Unequal Access
The summit, a continuation of ACCC’s Metastatic Breast Cancer Project launched in 2016, centered around the recognition that there are significant disparities in the resources available to patients. These disparities may be a function of geography, racial inequities, lack of insurance, lack of personal finances, insufficient support systems, unequal access to clinical trials, or other factors outside the control of individual patients. Before the summit, participants were asked to prioritize the issues they think most need addressing in metastatic breast cancer care. Respondents gave the highest priority to patients’ inability to adequately access new and emerging treatments, followed by poor access to clinical trials and poor care coordination and communication.
Throughout the summit, participants emphasized the need to recognize that breast cancer is not a monolithic disease. The many ways in which the disease manifests itself and the diversity of treatments available—many still in the clinical trial phase—mean that patients with metastatic breast cancer will not necessarily be well-served by the “survivorship mantra” often embraced by patients diagnosed with early-stage breast cancer.
Rather, participants agreed, patients with metastatic breast cancer should have access to resources that are customized to their specific needs. Participants acknowledged that while many of these resources—such as clinical navigation services and peer support groups—are already well developed and available to some patients, many others lack access to them. As one participant noted, “The future is already here, but it is not evenly distributed.”
To address this inadequate distribution of resources, summit attendees participated in an exercise that resulted in six recommended action items that rank high in both feasibility and potential impact:
A full executive summary of the main findings of ACCC’s Metastatic Breast Cancer Summit will soon be available online. For additional insight into the availability of supportive care services to metastatic breast cancer patients, view ACCC’s Multidisciplinary Team Communication in Metastatic Breast Cancer 2019 Survey Highlights. To learn more about ACCC’s Metastatic Breast Cancer project, contact Elana Plotkin, ACCC Provider Education.
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
